Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - June 30, 2018
(WorldNews Sweden)

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - June 30, 2018 Message from the CEO The second quarter was dominated by extensive preparatory work relating to the pivotal phase III study, called `The Connection Study`. Our experience from the completed phase II study have contributed valuable insight that we utilize when designing The Connection Study. The preparations are considerable, as we plan to recruit more than 2 000 preterm infants, which is likely to be the largest study ever conducted in this particularly vulnerable population. As previously communicated, IBT has elected Premier Research International LLC, which was also IBT`s contract research...